Pardes Biosciences Shares Early Data From COVID-19 Study


Pardes Biosciences Inc's PRDS has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Conference on Retroviruses and Opportunistic Infections (CROI) 2022. 

  • The presentation shared details around the nonclinical profile of PBI-0451 and interim clinical safety, tolerability, and pharmacokinetics (PK) after single- and multiple ascending doses.
  • PBI-0451 has been generally well tolerated over a >20-fold single- and >14-fold multiple-total daily dose range. 
  • Related: Pardes Biosciences Clears IND Application For Oral Antiviral Candidate For COVID-19.
  • All treatment-emergent adverse events in the study reported through January 31 have been assessed as mild in severity and resolved without intervention.
  • In a drug-drug interaction cohort, the pharmacokinetics of PBI-0451 was not substantially affected when co-administered with ritonavir.
  • In multiple ascending dose cohorts, interim data showed that PBI-0451 twice-daily achieved and maintained PK exposures.
  • The Company believes the candidate can provide potent antiviral activity against COVID-19 and emerging variants.
  • Additional dose cohorts and PK evaluation in this ongoing Phase 1 study continue.
  • The Company will inform dose selection for the upcoming PBI-0451 Phase 2/3 study anticipated to start mid-2022.
  • Price Action: PRDS shares are down 1.39% at $12.03 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsCOVID-19 CoronavirusPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!